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Tick saliva antibodiesTicks transmit numerous pathogens, including borreliae, which cause Lyme disease. Tick saliva con-
tains a complex mix of anti-host defense factors, including the immunosuppressive cysteine-rich
secretory glycoprotein Salp15 from Ixodes scapularis ticks and orthologs like Iric-1 from Ixodes ric-
inus. All tick-borne microbes beneﬁt from the immunosuppression at the tick bite site; in addition,
borreliae exploit the binding of Salp15 to their outer surface protein C (OspC) for enhanced trans-
mission. Hence, Salp15 proteins are attractive targets for anti-tick vaccines that also target borreliae.
However, recombinant Salp proteins are not accessible in sufﬁcient quantity for either vaccine man-
ufacturing or for structural characterization. As an alternative to low-yield eukaryotic systems, we
investigated cytoplasmic expression in Escherichia coli, even though this would not result in glyco-
sylation. His-tagged Salp15 was efﬁciently expressed but insoluble. Among the various solubility-
enhancing protein tags tested, DsbA was superior, yielding milligram amounts of soluble, mono-
meric Salp15 and Iric-1 fusions. Easily accessible mutants enabled epitope mapping of twomonoclo-
nal antibodies that, importantly, cross-react with glycosylated Salp15, and revealed interaction sites
with OspC. Free Salp15 and Iric-1 from protease-cleavable fusions, despite limited solubility, allowed
the recording of 1H–15N 2D NMR spectra, suggesting partial folding of the wild-type proteins but not
of Cys-free variants. Fusion to the NMR-compatible GB1 domain sufﬁciently enhanced solubility to
reveal ﬁrst secondary structure elements in 13C/15N double-labeled Iric-1. Together, E. coli expression
of appropriately fused Salp15 proteins may be highly valuable for the molecular characterization of
the function and eventually the 3D structure of these medically relevant tick proteins.
 2015 The Authors. Published by Elsevier B.V. on behalf of the Federation of European Biochemical Societies. This
is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
Ticks are obligate ectoparasites that infest nearly all verte-
brates. After mosquitos they comprise the second-largest group
of arthropod vectors, transmitting numerous pathogenic viruses,
bacteria and protozoa, with a high public health and economic
impact [1]. Prominent examples for tick-borne human disease
agents are tick-borne encephalits virus [2,3] and various Borrelia
species causing Lyme disease [4–6]; the main agents are Borrelia
burgdorferi sensu stricto in North-America, and B. burgdorferi plusBorrelia garinii and Borrelia afzelii in Eurasia. Each step of the tick
life-cycle through the larval, nymphal and adult stages requires a
bloodmeal. Ixodid (‘‘hard’’) ticks, including Ixodes scapularis and
Ixodes paciﬁcus from North-America and Ixodes ricinus from Eurasia
as prime human disease-relevant species, take long-term (several
days) bloodmeals. This exposes the engorged tick to numerous
host defenses, such as vasoconstriction, complement activation,
and innate and adaptive immune responses [6]. Tick saliva there-
fore contains a complex cocktail of counteracting factors, including
immunosuppressants [7]. As yet few of these factors have been
characterized; one of the best-studied is the salivary protein
Salp15 from I. scapularis [8,9], a secretory cysteine-rich glycopro-
tein of about 15 kDa (in unglycosylated form). Salp15 binds to
the T cell coreceptor CD4, compromising IL-2 production and
thereby T cell activation and proliferation [8,10], and also dendritic
cell-speciﬁc adhesion receptor DC-SIGN [11], further inhibiting
cytokine expression. Less well characterized Salp 15 orthologs
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(Fig. 1) in I. ricinus which shares 76% sequence identity with
Salp15 [12]. Salp15 and its orthologs are synthesized as about
135 aa precursors predicted to contain cleavable N terminal signal
sequences of around 20 aa. The predicted cleavage sites vary
slightly, depending on the speciﬁc ortholog and prediction
algorithm.
Tick-borne pathogens proﬁt generally from the local immuno-
suppression at the tick feeding site which facilitates their transmis-
sion [13–15]. B. burgdorferi exploits on top the speciﬁc binding to
Salp15 of its outer surface protein C (OspC) to provide itself with
a protective coat against both innate and adaptive immune
responses, thus enhancing dissemination in the host [16]. Similar
binding of Iric-1 to the respective OspC proteins from the Eurasian
Lyme disease-relevant borreliae suggests an analogous role [17].
Based on these data, Salp15, and by inference Iric-1, have
gained interest as targets for anti-tick vaccines [18,19] which
might reduce tick infestation and tick-borne pathogen transmis-
sion in general, and Borrelia transmission in particular. After with-
drawal of a ﬁrst-generation, lipidated B. burgdorferi OspA-based
Lyme disease vaccine and with >100.000 conﬁrmed new cases of
Lyme disease per year in Europe and the US the need for improved
vaccines is obvious; moreover, the actual number of Borrelia infec-
tions may be severely underdiagnosed [4,20]. An experimental
Salp15-based vaccine has indeed shown some promise in a mouse
model [21]. However, there is currently no expression system that
would allow to produce recombinant Salp15 in sufﬁcient quantity
for vaccine manufacturing. Moreover, this scarcity of material is
responsible for the complete lack of structural knowledge on
Salp15 and other tick saliva proteins, including the location of
potentially neutralizing epitopes. Furthermore, it prevents the
rational design of advanced vaccines, e.g. presentation on
immune-enhancing nanocarriers such as virus-like and virus cap-
sid-like particles, respectively (e.g. [22]; Kolb, Nguyen, Walker
and Nassal, Viral Nanotechnology, CRC Press; in press) or epi-
tope-focused vaccines [23]. Conversely, immune-enhancement
will be mandatory to overcome the immunosuppressive activity
of Salp15 [8] and, likely, of its orthologs.
The major challenge for recombinant expression of Salp15 and
related proteins is their presence in tick saliva as glycosylated pro-
teins of unknown structure that contain seven cysteines of
unknown disulﬁde status. Virtually all previous studies were
restricted to the secretory expression of Salp15 in stably transfec-
ted Drosophila melanogaster S2 cells [8]. While likely producing a
near-authentic tick protein, the yields from this system are very
low. Explicit numbers have not been published, yet in our own
experiments we hardly reached yields above 50 ng/ml of S2 cell
culture (R.W. and J.H.; unpublished data). Furthermore, the use
of stable cell clones greatly hampers generation of mutant Salp15
which would be instrumental for the identiﬁcation of functional
interaction sites. We also failed to achieve substantially higher
yields using Salp15-encoding baculoviruses and SF9 insect cells,
or transiently or stably Salp15 transfected Leishmania tarentolaeFig. 1. Primary sequence features of I. scapularis Salp15 and I. ricinus Iric-1. The sequen
indicated by dots, or where emphasizing a speciﬁc feature, by lower case lettering.
glycosylation motifs in red. Cys residues are high-lighted by yellow background and cons
position of Ser71 in Salp15. A more comprehensive alignment of Salp15 orthologs is pro(P.K., J.V., M.N.; unpublished data). Hence here we focused on Esch-
erichia coli as expression host. Conventionally, eukaryotic secretory
cysteine-rich proteins are expressed in the E. coli periplasm [24] to
allow for disulﬁde-formation, however often at the cost of low
yield [25]. Conversely, expression in the reducing cytoplasm suf-
fers from the lack of disulﬁde formation, often accompanied by
general folding problems resulting in insolubility [24]. This was
indeed observed for a construct in which the N terminal 19 resi-
dues of full-length Salp15 (essentially the signal sequence) were
replaced by an artiﬁcial 28 aa sequence providing an N terminal
His6 tag (NH6-Salp15) which was well expressed but virtually
insoluble. While this protein could be solubilized from inclusion
bodies and be used to generate Salp15-speciﬁc mAbs (see below),
its structural status remained unknown.
A potential alternative was to express Salp15 as a fusion with a
solubility enhancing protein tag in an E. coli strain engineered to
provide a more oxidizing cytosolic environment such as SHufﬂe
Express (NEB). These cells express, in addition, a cytoplasmic ver-
sion of the periplasmic disulﬁde isomerase DsbC; this may enable
reshufﬂing of potentially improper disulﬁde bonds [26]. Various
proteins, e.g. maltose-binding protein (MBP) and glutathione-S-
transferase (GST), are in use as solubility enhancing tags [27,28].
Also thioredoxin (Trx) superfamily members like Trx itself, or cyto-
solic versions of DsbC or DsbA [29], a likewise periplasmic thiol
oxidoreductase, have in some instances successfully been applied
for the soluble expression of cysteine-containing proteins [24]. In
fact, a Trx-Salp15 fusion protein was used to demonstrate the sup-
pressive impact of the Salp15 part on the induction of Trx-speciﬁc
antibodies [8], but yields and solubility were not reported.
As shown below, out of various combinations of fusion partners
and E. coli expression strains, expression of Salp15 and Iric-1 as
DsbA fusions in SHufﬂe Express cells resulted in milligram
amounts of soluble proteins per liter of E. coli culture. The easy
access to variants provided by this system enabled us to deﬁne
the epitopes of two Salp15/Iric-1 cross-reactive mAbs and to map
the OspC interaction sites to a predicted a-helical segment around
aa 50 (numbering based on the uncleaved precursor proteins). Free
Salp15 and Iric-1 from protease-cleavable DsbA fusions, and more
so fusions with the NMR-compatible GB1 tag, allowed production
of 15N and 13C/15N labeled samples for heteronuclear NMR spec-
troscopy, giving preliminary insights into secondary structure ele-
ments in Iric-1 and paving the way for determining the 3D
structure of these medically relevant tick saliva proteins.
2. Results
2.1. DsbA as efﬁcient solubility-enhancing fusion partner for Salp15
In a ﬁrst series of experiments we inserted the open reading
frame (ORF) of mature Salp15 (starting with residue A20, at the
predicted signal peptide cleavage site; see Fig. 1) into bacterio-
phage T7 promoter-controlled vectors providing the ORFs for N
terminally His6-tagged versions of the protein tags MBP, GST,ces represent the uncleaved precursor proteins. Amino acid identities in Iric-1 are
Predicted signal sequences (Salp15: 1-20; Iric-1: 1–24) are shown in italics, N-
ecutive numbering C1, C2 etc. Note that Iric-1 lacks one residue, by alignment at the
vided in Fig. S1.
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and Cys33 in the catalytic C-X-X-C motif [30] were either replaced
by Ser-residues (termed DsbA) to minimize potentially improper
disulﬁde formation between DsbA and Salp15 [31], or were main-
tained (termed DsbA*) to possibly promote proper disulﬁde forma-
tion in the Salp15 part. Later on, the immunoglobulin-binding
domain 1 from protein G (GB1), a small (56 aa) NMR-compatible
tag [32], was employed as additional fusion partner.
In E. coli BL21* Codonplus (CP) RIL cells (Stratagene), providing
IPTG-inducible T7 RNA polymerase plus rare E. coli tRNAs from the
CP plasmid, IPTG induction led to visible overexpression of all
fusion proteins; however, only the MBP and DsbA fusions (and in
part the corresponding GB1 fusions, see below) were well soluble
(Fig. 2B). The same was observed in T7 SHufﬂe Express cells carry-
ing the CP plasmid (referred to as SHexpCP cells). However, the
fraction of DsbA-Salp15 remaining in the insoluble fraction of the
native bacterial lysates was reproducibly lower than in BL21*CP
cells (Fig. 2C, left panel, lanes P), and the soluble fraction contained
lower levels of smaller expression vector-related products migrat-
ing around the 25 kDa marker position. A comparably beneﬁcial
effect of the SHexpCP strain was observed for Salp15 fused toFig. 2. Impact of fusion partner and E. coli expression strain on Salp15/Iric-1 solubilit
sequences starting with A20 were fused to various solubility-enhancing domains (SEDs
sequence was inserted in-between. (B) Differential solubility enhancement by different p
BL21*CP cultures expressing the indicated Salp15 fusion proteins were analyzed by SD
Salp15 protein sequence. Total protein (T) in native lysates, and in the insoluble pellet (P)
panel: DsbA-Salp15 expressed in BL21*CP versus SHexpCP cells. Note the lower level of
versus DsbA-Iric-1 expressed in SHexpCP cells. Note the lower level of DsbA-Iric-1 in thMBP and DsbA* (not shown), and to GB1 (see Fig. S5). Because of
DsbA’s considerably smaller size (23 kDa) compared to MBP
(40 kDa), and the lack of positive impact of the Cys-containing
DsbA* versus Cys-less DsbA (see below; Fig. 10A), most subsequent
constructs were based on DsbA and expressed in SHexpCP cells.
This combination worked also well for Iric-1, which was obtained
in almost completely soluble form (Fig. 2C, right panel). An intrin-
sically higher solubility of Iric-1 compared to Salp15 was con-
ﬁrmed in various subsequent experiments.
2.2. Soluble Salp15 and Iric-1 DsbA fusion proteins are monomeric
For preparative puriﬁcation, the soluble fractions of lysates
from induced cultures of SHexpCP cells transformed with the
DsbA-Salp15 and DsbA-Iric-1 vectors were ﬁrst subjected to immo-
bilized Ni2+ ion afﬁnity chromatography (IMAC). Full-length
(35.5 kDa) DsbA-Salp15 eluted between 50 and 300 mM imidaz-
ole, however accompanied by nearly equal amounts of smaller
(25 kDa) products (Fig. 3A, left panel). As a protease inhibitor
cocktail was present during the entire work-up, we suspected
these products to arise from translation initiation at they. (A) General structure of the expression constructs used. The Salp15 and Iric-1
) carrying an N terminal His6-tag; in some constructs, a TEV protease recognition
rotein tags. Total SDS-lysates versus the soluble fraction of native lysates from E. coli
S–PAGE followed by Coomassie Blue staining. (C) Impact of expression strain and
versus soluble supernatant (S) after centrifugation were analyzed by SDS–PAGE. Left
fusion protein in the insoluble pellet from SHexpCP cells. Right panel: DsbA-Salp15
e insoluble pellet.
Fig. 3. Representative puriﬁcations of the DsbA fusion proteins. (A) DsbA-Salp15. (B) DsbA-Iric-1. Cleared native lysates were ﬁrst subjected to IMAC using a Ni-NTA column
developed using a linear imidazole gradient. Peak fractions were concentrated and subjected to SEC on Superdex S75. Fractions were analyzed by SDS–PAGE followed by
Coomassie Blue staining. The arrowhead marks the elution volume of a 44 kDa size marker protein. The positions of full-length (FL) and truncated (TR) fusion proteins are
indicated. Note the lower level of truncated products for DsbA-Iric-1 compared to DsbA-Salp15.
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would result in a 25 kDa protein; however, mutation of M91 to
Leu did not signiﬁcantly change this pattern (not shown), suggest-
ing the fusion protein is highly sensitive to proteolytic cleavage.
Depletion of the smaller products by subsequent size exclusion
chromatography (SEC) on Superdex 75 (Fig. 3A, right panel)
allowed the isolation of 30% of the total DsbA-Salp15 protein in
>90% purity in a single run, as estimated from densitometric scan-
ning of the Coomassie-Blue stained SDS–PAGE gel, in an overall
yield of around 8 mg/L culture. By comparison with a set of molec-
ular mass standards, the full-length fusion protein eluted at a vol-
ume corresponding to an apparent molecular mass of 42 kDa,
consistent with a monomeric state. Similar results were obtained
with the DsbA-Iric-1 fusion protein, except that the smaller prod-
ucts co-eluting from the IMAC column were much less abundant
(Fig. 3B, left panel) and could be more efﬁciently separated from
the full-length protein by SEC (Fig. 3B, right panel); this increased
the yield of pure full-length DsbA-Iric-1 protein to about 30 mg/L
culture. The elution volume of the Iric-1 protein was again in line
with a monomeric state.
Together these data demonstrated that highly enriched Salp15
and Iric-1 are accessible from E. coli in milligram amounts per liter
of culture as soluble, monomeric DsbA fusion proteins.
2.3. Mapping of mAb epitopes using DsbA-Salp15 and DsbA-Iric-1
fusions
The solubilized NHis-Salp15 preparation, available before the
above reported results were obtained, was used to generate mono-
clonal antibodies (mAbs) 19/7.4 and 18/12.1 (R.W. and J.H., unpub-
lished data). In order to map their epitopes, we ﬁrst generated a
panel of DsbA-Salp15 proteins in which from one to all of the seven
Cys-residues (Fig. 4A) were replaced by Ser-residues (termed
Salp15Cx, where x speciﬁes the replaced Cys-residue(s); variants
lacking all cysteines were named Salp15Cys and Iric-1Cys). Allwere efﬁciently expressed in soluble form (Fig. 4B, top panel). We
also included, as the ﬁrst ones in a series (see below), two trun-
cated Salp15 variants lacking the N terminal 44 aa (SaDN44) or
the C terminal aa from position 115 on (SaDC115); these trunca-
tions appeared to enhance proteolytic sensitivity, as suggested by
the reduced presence of full-length versus faster migrating prod-
ucts. When used as test antigens on Western blots, all proteins
were similarly recognized by mAb 19/7.4 (Fig. 4B, middle panel),
suggesting its epitope did not involve any of the Cys-residues
and was contained between Salp15 residues 45 and 114. The latter
was also true for mAb 18/12.1, however the Cys-variants were dif-
ferentially recognized. The common feature of all non-reactive
variants was the absence of C93 (C2) and C97 (C3). This was con-
ﬁrmed for Iric-1 in a side-by-side comparison of the wild-type ver-
sus Cys-free variants of Salp15 and Iric-1 DsbA fusion proteins
(Fig. 4C).
For further mapping, we employed additional terminal trunca-
tion variants (Fig. 5A). The shortest ones still recognized by both
mAbs (Fig. 5B) lacked the ﬁrst 59 aa (SaDN59), or the C terminal
residues from aa 100 on (SaDC100). To ﬁne-map the epitopes,
we fused various Salp15 and Iric-1 sequences from within that
region to DsbA. The fusion containing Salp15 residues I83-H99,
which are strictly conserved in Iric-1 (Fig. 1), reacted with both
mAbs. However, within that sequence mAb 19/7.4 recognized only
the subsegment I83-N92, and mAb 18/12.1 only the subsegment
D89-H99. Hence the epitopes are closely juxtaposed but distinct.
Notably, the latter segment contains C93 (C2) and C97 (C3), which
were also required for recognition by mAb18/12.1 in the context of
full-length Salp15 (Fig. 4). Reactivity of both mAbs with DsbA-
Salp15 and DsbA-Iric-1 full-length proteins was also conﬁrmed in
an ELISA format where the two proteins were coated onto the plate
(data not shown; but see OspC binding below).
To test for reactivity of the mAbs with authentic Salp15 we
investigated their ability to recognize glycosylated Salp15, in par-
ticular because in both Salp15 and Iric-1 one of the N-glycosylation
Fig. 4. Impact of Cys-mutations on DsbA-Salp15 recognition by mAbs 19/7.4 and
18/12.1. (A) Cysteine-map of DsbA-Salp15. For reference to the explicit aa positions,
see Fig. 1. DsbA-Salp15 proteins with one to all seven cysteines (Cys) replaced by
Ser-residues were expressed in SHexpCP cells; the number(s) in their names
indicate the replaced cysteine(s). For comparison, an N terminal (SaDN44) and a C
terminal truncation variant (SaDC115) were included. (B) SDS–PAGE analysis and
immunoblots. Owing to the high expression levels, total SDS lysates could be used.
Three SDS–PAGE gels were run in parallel. The ﬁrst (upper panel) was stained with
Coomassie Blue. The second and third, loaded with one ﬁfth the amount of samples,
were blotted and probed with the indicated mAbs, followed by visualization using a
peroxidase-conjugated anti-mouse secondary antibody and a chemiluminescent
substrate. Note the failure of mAb 18/12.1 to detect any of the proteins lacking C2
and C3. (C) Cross-reactivity of anti-Salp15 mAbs with Iric-1. DsbA fusions of wild-
type Salp15 and Iric-1 and their Cys-free variants were separated by SDS–PAGE and
immunoblotted as in (B).
Fig. 5. Mapping the epitopes of mAbs 19/7.4 and 18/12.1. (A) Schematic overview
of the constructs used. Perpendicular marks on the box representing the Salp15
(Iric-1) ORF indicate the positions of the seven Cys-residues. Salp15 (Sa) derivatives
are indicated as black lines, Iric-1 (Ir) derivatives as grey lines. Reactivities with the
two mAbs derived from immunoblotting results are summarized on the right. (B)
SDS–PAGE analysis and immunoblots. The indicated DsbA fusion proteins were
analyzed as in Fig. 4B. Note that the Salp15 sequence 83-99, the smallest internal
segment recognized by both mAbs, is identical to the Iric-1 sequence 82-98 (Fig. 1).
(C) Salp15 primary sequences encompassing the epitopes of mAbs 19/7.4 and 18/
12.1.
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overlaps with the epitopes (see Fig. 1). To this end, we transfected
eukaryotic expression vectors encoding three potentially secreted
variants of Salp15 (Fig. 6A), carrying the authentic Salp15 signal
sequence (Salp-Sig-Salp15) or that of the E. coli OmpA protein
(OmpA-Sig-Salp15), into human HEK293 cells. To account for
potential non-reactivity with the mAbs, all constructs were pro-
vided with a C terminal His6 tag to allow detection with an
anti-His antibody and enrichment by Ni-NTA afﬁnity capture. To
possibly increase detection sensitivity, a third construct (Salp-
Sig-NH6-Salp15) contained an additional His6 tag after the pre-
dicted signal sequence cleavage site. Cells transfected with a vector
for intracellular eGFP expression and non-transfected cells servedas controls. Four days post transfection, equal aliquots of the cul-
ture supernatants were incubated with Ni-NTA agarose beads,
and the afﬁnity-captured material was used for immunoblotting,
either directly or after prior treatment with peptide-N-glycosidase
(PNGase) F for glycan removal. Detection with an anti-His-tag anti-
body (Fig. 6B, left panel) revealed for all three Salp15 proteins the
presence of smeary bands above the 25 kDa marker position which
collapsed into distinct 20 kDa bands after PNGase F treatment, in
line with the secretion of heterogeneously glycosylated Salp15
from the cells. Equal aliquots of the Ni-NTA pulled-down material
from the Salp-Sig-NH6-Salp15 transfected cells were then again
subjected to immunoblotting, using either the anti-His-tag anti-
body or mAbs 19/7.4 and 18/12.1. All three antibodies reacted well
the main product obtained after PNGase F treatment (Fig. 6B, right
panels) yet, importantly, also with the glycosylated forms. Because
glycan shielding of the epitopes might depend on 3D structure, we
also tested the reactivity of both mAbs with native glycosylated
Salp15 in an ELISA format. To this end, the secreted Salp15 proteins
were afﬁnity-captured on Ni-NTA HisSorb microtiter plates.
Fig. 6. Recombinant Salp15 induced mAbs crossreact with secreted, glycosylated
Salp15. (A) Schematic representation of the constructs used. All constructs
contained a C terminal His6 tag to allow mAb-independent detection and afﬁnity
capture via Ni-NTA supports but differed regarding their N terminal signal
sequences. Construct Salp-Sig comprises the original Salp15 precursor sequence;
in Salp-Sig-NH6 a second His6-tag was inserted after the signal sequence; in OmpA-
Sig the Salp15 signal sequence was replaced by the E. coli OmpA signal sequence.
Lightning symbols, predicted signal peptide cleavage sites. (B) Immunoblot
analysis. Constructs from (A) were transfected into HEK293 cells. Proteins in the
supernatants captured using Ni-NTA beads were analyzed by immunoblotting
without, or with prior deglycosylation using PNGase F. Left panel: Anti-His-tag
immunoblot. Right panels: Detection of secreted Salp-Sig-NH6 proteins using an
anti-His-tag mAb or mAbs 18/12.1 and 19/7.4. (C) ELISA. Wells of a His-Sorb
microtiter plate were incubated, or not (ø), with the indicated recombinant Salp15
proteins, or 200 ll of culture supernatant from cells transfected with empty vector
(mock) or vectors for eGFP or Salp-Sig-NH6, followed by incubation with the mAbs
and detection by peroxidase-conjugated secondary antibody and TMB as substrate.
All measurements were performed in quadruplicate; error bars indicate standard
error of the mean (SEM).
Fig. 7. DsbA-Salp15 and DsbA-Iric-1 both interact speciﬁcally with different
Borrelia OspC proteins. ELISA plate wells were coated with the indicated
recombinant OspC proteins from B. burgdorferi (OspCa, Ospb) or B. afzelii (OspC
A3, OspC YU), then incubated with DsbA-fused wt or Cys Salp15 or Iric-1. Bound
tick proteins were detected using mAb 19/7.4 as in Fig. 6C. All measurements were
performed in quadruplicates; error bars indicate SEM. An analogous ELISA using
mAb 18/12.1 is shown in Fig. S2.
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and from non-transfected cells served as negative controls, E. coli
derived DsbA-Salp15 (100 ng and 10 ng per well) and solubilized
NHis-Salp15 (10 ng per well) as positive controls. As shown in
Fig. 6C, both mAbs generated signals with the Salp-Sig-NH6-Salp15
samples that clearly exceeded those of the negative controls. For
mAb 18/12.1 the signal intensity (from 200 ll supernatant) was
similar to that produced by 10 ng DsbA-Salp15 or, accounting for
the DsbA part, by 3.5 ng recombinant Salp15. This translates into
about 20 ng Salp15 per ml of culture supernatant and thus is in a
similarly low range as seen in stably transfected insect cells.
Together, these data imply that glycosylation does not shield the
epitope of either mAb; hence both might be able to neutralize
Salp15 from tick saliva.2.4. DsbA-Salp15 and DsbA-Iric-1 are functional in OspC binding and
allow mapping of the OspC binding sites
A distinct biological property of Salp15 and Iric-1 discovered
using insect cell-derived proteins is their interaction with OspC
[21,33]. To assess the ability of the E. coli expressed tick proteins
to recapitulate this interaction we set up an ELISA in which four
different recombinant OspC proteins (see Materials and Methods),
OspCa and OspCb from B. burgdorferi strain ZS7 (with 96%
sequence similarity), and B. afzelii NE [34] OspC A3 and OspC YU
(with sequence similarities of about 75% to each other and to the
ZS7 isolates), were coated on the plate (100 ng/well). Wells with-
out OspC coating served as negative control. Next, the wells were
incubated with excess (1 lg/well) DsbA-fusion proteins carrying
wild-type or Cys-free Salp15 and Iric-1. Potentially bound tick pro-
teins were detected using mAb 19/7.4. All combinations of OspC
and Salp15/Iric-1, but not the negative controls, gave strong signals
(Fig. 7). While the reason for the particularly intense signals with
Cys-free Salp15 remains to be determined, this result indicated
that OspC binding does not depend on the tick-protein Cys-resi-
dues. Regarding OspC speciﬁcity, the OspCs from B. burgdorferi
were reproducibly better bound than those from B. afzelii. This
ranking was corroborated by comparable results using mAb 18/
12.1 for detection (Fig. S2); the results also conﬁrmed in a non-
denaturing ELISA setting that this mAb does not recognize the
Cys-free variants. Speciﬁcity of the interaction between recombi-
nant Salp15 and Iric-1 and OspC was further conﬁrmed in a reverse
setting where the DsbA-fusions were coated on the plate, followed
by incubation with the various OspC proteins and their detection
by the OspC-speciﬁc mAb LA97.1 [35]. For lack of reactivity with
OspC A3 and OspC YU of this mAb, these data were restricted to
the B. burgdorferi OspC proteins (not shown).
Together, these data demonstrated the ability of E. coli derived
Salp15 and Iric-1 to speciﬁcally interact with OspC proteins from
the major Borrelia species in North-America and Eurasia, with
implications for anti-tick saliva protein vaccines (see Section 3).
To map the OspC interaction site(s) on Salp15 and Iric-1, OspCa
coated ELISA plates were incubated with the terminally truncated
(but mAb 19/7.4 reactive) DsbA-Salp15 and DsbA-Iric1 fusion pro-
teins (see Fig. 5), followed by detection of potentially bound tick
proteins by mAb 19/7.4. The most pertinent results are shown in
Fig. 8A. Accordingly, C terminal deletions after aa 100 (SaDC100)
and N terminal deletion before aa 44 (SaDN44) had no negative
effect. However, deleting 50 aa from the N terminus of Iric-1
Fig. 8. Mapping of the OspC interaction sites on Salp15 and Iric-1. (A) OspC binding ELISA. ELISA plate wells were coated with recombinant OspCa as in Fig. 7, then incubated,
or not (ø), with the indicated DsbA-fused deletion variants (see Fig. 5A) of Salp15 or Iric-1. Bound tick proteins were detected using mAb 19/7.4 as in Fig. 6C. (B) Expression of
internal Salp15 and Iric-1 fragments 48-67 as C terminal fusions to N terminally His-tagged GFP. Upper panel: Schematic representation of the constructs. Lower panel: SDS–
PAGE analysis of the peak fractions after IMAC puriﬁcation of the GFP proteins expressed in E. coli. Material from these fractions was used in the ELISA shown in (C). (C)
Selective binding to OspC of the tick protein fragment-bearing GFP fusions. For the assays to the left of the dashed line (‘‘direct immob.’’), the ELISA plate wells were directly
coated, or not (ø), with the GFP fusion proteins. For the remaining assays, the wells were coated with OspCa as in (A), then incubated with NH6-GFP (ø) or the tick protein
fragment bearing variants, or DsbA-SaDN59 which did not bind OspCa. Bound GFP proteins were detected using an anti-GFP mAb. Assays were performed in quadruplicates;
error bars represent SEM.
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stantially decreased signal strength, suggesting the OspC interac-
tion site(s) to involve residues downstream of aa 44. For ﬁnal
conﬁrmation, we fused the sequence from P48 to D67 of Salp15,
or P48 to N67 of Iric-1, to an N terminally His6-tagged eGFP
(Fig. 8B); the same eGFP protein without fused peptide served as
control. All eGFP proteins were well and solubly expressed in E. coli
(Fig. 8B, bottom panel). After enrichment by IMAC, they were incu-
bated with plate-immobilized OspCa (Fig. 8C, ‘‘OspCa-mediated
binding’’); binding was detected using an anti-GFP mAb (Chromo-
tek); functionality of the assay was conﬁrmed by direct immobili-
zation of the peptide-fused GFP proteins to the ELISA plate (Fig. 8C,
‘‘direct immob.’’). Strong signals in the OspCa-mediated format
were detected for both peptide-fused eGFP proteins, but not the
eGFP-only control. Speciﬁcity was further corroborated by the
absence of signal when the OspCa coated wells were incubated
with the DsbA-SaDN59 protein. Hence the sequences comprising
residues P48-D67 of Salp15 and P48 to N67 of Iric-1 were neces-
sary and sufﬁcient for speciﬁc OspC binding.
2.5. E. coli derived Salp15 and Iric-1 proteins for NMR structural
analyses
The high level soluble expression in E. coli plus their functional-
ity in antibody and OspC binding suggested the DsbA fusions with
Salp15 and/or Iric-1 as a source of proteins suitable for direct struc-
tural analyses, e.g. by NMR spectroscopy. 3D structure determina-
tion by NMR typically requires up to 0.5 ml of aP0.1 mM protein
solution (1.5 mg/ml for a 15 kDa protein) and access to 15N and 13C
isotope labeled derivatives. With about 100 aa in length, the tick
proteins fall well into the range of protein NMR [36,37]; however,
the larger DsbA parts in the fusion protein would convolute the
spectra. To obtain DsbA-free Salp15 and Iric-1, we therefore intro-
duced a TEV protease recognition sequence between DsbA and
Salp15, Iric-1, or their Cys-free variants, respectively (see
Fig. 2A). All constructs were as highly expressed in SHexpCP cells
as the parental fusion proteins, were mostly soluble, and could
be enriched by sequential IMAC and Superdex 75 SEC where they
eluted at a volume indicative of a monomeric state; also their rec-
ognition by mAb 19/7.4 (all) and 18/12.1 (only the wild-type pro-
teins) was the same as for the parental DsbA fusions (data not
shown).Next, the puriﬁed fusion proteins were subjected to cleavage by
His6-tagged TEV protease. For the wild-type Salp15 fusion this
produced a distinct SDS–PAGE gel band running at about 27 kDa
that corresponded to the DsbA part (nominally 24 kDa) and prob-
ably the TEV protease, plus a weakly Coomassie Blue staining band
of around 20 kDa (Fig. 9A, left panel) whose identity as free Salp15
was conﬁrmed by immunoblotting with mAb 19/7.4 (not shown).
Taking advantage of the His6-tags on the TEV protease and DsbA,
free Salp15 was obtained in the ﬂow-through of a Ni-NTA column
whereas the bulk of uncleaved precursor, cleaved DsbA and TEV
protease eluted, as expected, only at higher imidazole concentra-
tion (Fig. 9A, right panel). Attempts to concentrate the protein from
the ﬂow-through by ultraﬁltration indicated an upper solubility
limit of about 0.1 mg/ml, thus limiting its suitability for further
characterization (see below). Salp15Cys analogously released
from a DsbA-TEV fusion protein was more well-behaved (Fig. S3).
This also held for free Iric-1 (Fig. 9B, left panel) and its Cys-free var-
iant (Fig. 9B, right panel) which could both be concentrated to up to
0.5 mg/ml. Notably, both released tick proteins, independent
from their Cys-content, migrated more slowly during SDS–PAGE
than expected from their nominal molecular mass of 13 kDa;
Salp15 comigrated with a 18 kDa marker protein, Iric-1 had a
slightly higher mobility (see Fig. 9B, left panel, for a direct compar-
ison). Probably this reﬂects their high content (25%) of charged
amino acids [38].
To test for a potentially beneﬁcial effect on solubility of the
released tick proteins we also expressed them as fusions with cys-
teine-containing, i.e. potentially redox-active, DsbA (DsbA*). In all
aspects of expression level, solubility, puriﬁcation, and TEV-prote-
ase cleavage no signiﬁcant differences to the fusions with Cys-free
DsbA were observed (data not shown). To reveal potential differ-
ences in disulﬁde status, Iric-1 released from the DsbA versus the
DsbA* fusion protein were subjected, after blocking free SH groups
by iodoacetamide, to SDS–PAGE under non-reducing versus reduc-
ing conditions (Fig. 10A). In the absence of reducing agent, only
trace amounts (<5% as determined by densitometry) of a band with
a mobility expected for dimeric Iric-1 was seen in both prepara-
tions; at the monomer position one major band comigrating with
the reduced samples plus a weaker, faster migrating band were
observed, possibly reﬂecting a species with more extensive intra-
molecular disulﬁde bonding. However, the overall similar band
patterns revealed no advantage of the DsbA* versus the DsbA
Fig. 9. Free Salp15 and Iric-1 by TEV protease-mediated release from DsbA-TEV fusions. Wild-type (wt) and Cys-free (Cys) forms of Salp15 and Iric-1 were expressed as
DsbA fusions carrying a TEV protease recognition site between the two domains (see Fig. 2A) and enriched by Ni-NTA IMAC. Material from the peak fractions was used as
protease substrate. (A) Salp15. Left panel: SDS–PAGE comparison of untreated versus His-tagged TEV protease-treated DsbA-TEV-Salp15. Salp15 from a prior pilot scale
experiment served as reference (ref). Right panel: Depletion of uncleaved fusion protein, DsbA and TEV protease by IMAC. Free Salp15 was collected in the ﬂow-through; the
other protein components were retained due to their His-tags. Data for Cys-free Salp15 are shown in Fig. S3. (B) Iric-1. Wild-type (left panel) and Cys-free (right panel) DsbA-
TEV-Iric-1 proteins were treated as in (A). Aliquots analyzed by SDS–PAGE are labeled as follows: dig., TEV protease reaction; Ni-NTA ret., retained on Ni-NTA column; FT
10; ﬂow-through of Ni-NTA column, concentrated 10-fold by ultraﬁltration. Note the mobility difference between protease-released Iric-1 and Salp15.
Fig. 10. Basic structural features of free Salp15 and Iric-1. (A) Lack of impact of redox-active (DsbA*) versus inactive DsbA on Iric-1 disulﬁde status. Iric-1 was released by TEV
protease as in Fig. 9B from analogous fusion proteins comprising DsbA* carrying the catalytic C-X-X-C motif, or the Cys-free DsbA variant used throughout this study. Free
Iric-1 proteins were treated with excess iodoacetamide, then analyzed by SDS–PAGE under reducing (+DTT) versus non-reducing (DTT) conditions. The dominant band in
the non-reduced samples comigrating with the reduced samples plus a less intense faster migrating band are marked by arrows. The 24 kDa band marked by * was not
affected by DTT and hence does not represent a disulﬁde-linked Iric-1 dimer. (B) Structural heterogeneity of solubilized NH6-Salp15. Solubilized NH6-Salp15 was treated
with iodoacetamide and analyzed by SDS–PAGE under reducing versus non-reducing conditions as in (A). Note that nearly half the protein was present as disulﬁde-linked
dimer. (C) Protease-released and solubilized Salp15 differ in quaternary structure. Both proteins were subjected to SEC on Superdex 75. The elution volume of protease-
released Salp15 was consistent with a monomeric state, that of solubilized NH6-Salp15 with a dimeric state. (D, E) 1H–15N HSQC NMR spectra suggest a positive impact of the
tick protein cysteines on folding. Wild-type and Cys-free Salp15 (D) and Iric-1 (E) were released from 15N-labeled DsbA-TEV fusion proteins as in Fig. 9. Spectra from the wild-
type (wt; in black) and Cys-free (Cys; in red) proteins were superimposed to emphasize the broader peak dispersion of the wild-type proteins. Larger versions of the spectra
are shown in Fig. S4.
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fusions (data not shown).
As a potential alternative for structural studies the solubilized
NH6-Salp15 protein was subjected to the same type of analysis
(Fig. 10B). This revealed about half of the protein being present
as disulﬁde-linked dimer. To compare the native quaternarystructures of the DsbA-released Salp15 versus the solubilized
NH6-Salp15, both proteins were also subjected to analytical SEC
(Fig. 10C). The released Salp15 eluted around 79 ml, corresponding
to a molecular mass of 17.5 kDa. In contrast, the solubilized NH6-
Salp15 eluted at 73 ml, corresponding to about 30 kDa, i.e. twice its
nominal molecular mass of 15.6 kDa. Hence unless refolding condi-
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conformation, the renatured Salp15 does not appear suitable for
structural work.
Despite the limited solubility of the DsbA released tick proteins,
the procedure could be adapted to generate uniformly 15N labeled
derivatives of Salp15 and Iric-1 plus their Cys-free variants (see
Materials and Methods) in sufﬁcient quantity to record 2D
1H–15N heteronuclear single quantum coherence (HSQC) spectra.
These provide information about NH groups in the protein back-
bone and on nitrogen-containing aa side chains. A wide peak dis-
persion indicates a stable tertiary structure because the NMR-
active nuclei experience a variety of distinct three-dimensional
environments; a narrow peak dispersion is indicative of a lack of
stable tertiary structure and typically seen with intrinsically disor-
dered proteins or random-coil peptides [37]. DsbA-released Salp15
showed a modest peak dispersion which was drastically reduced in
its Cys-free variant (Fig. 10D; see Fig. S4A for higher magniﬁca-
tion). Hence Cys-free Salp15 is largely unstructured and/or highly
ﬂexible, whereas the Cys-residues in the wild-type protein contrib-
ute to holding at least parts of the protein in a stable conformation.
This was conﬁrmed, better visible due to the higher protein con-
centrations, for Iric-1 versus its Cys-free variant (Fig. 10E; seeFig. 11. GB1 tick protein fusions enable higher sample concentration and more detaile
form, were expressed and enriched by IMAC analogously to the DsbA fusions. (A) Salp
truncated products, requiring further puriﬁcation by SEC (left panel). Peak fractions cont
spectra (upper right panel; GB1-Salp15 peaks in blue; superimposed red peaks from free
allowing to omit the SEC step. Instead, ultraﬁltration (UF) through a 50 kDa MWCO m
ﬂow-through (FT) was then concentrated 16-fold using a 10 kDa MWCO membrane (1
the spectra are shown in Fig. S6. (C) Direct evidence for secondary structure of Iric-1 in
of the assigned regions of Iric-1 from the chemical shift values. The height of the bars
plots of the a-helix and b-strand relevant cross peaks (regions in the full-length seque
assigned N-terminal region of Iric-1 (N22-L45) does not contain any secondary structure
to TALOS-N.Fig. S4B for higher magniﬁcation). However, 3D structure determi-
nation requires, besides 13C/15N double-labeling, higher sample
concentrations than were accessible for the free tick proteins.
We therefore generated constructs carrying non-cleavable GB1
as fusion partner. N-terminal GB1 can increase solubility of the
fused partner protein, and due to its small size and stable fold does
not require removal prior to NMR analysis [32,39]. Under analo-
gous conditions as described above for the DsbA fusions, the
GB1-fusion proteins were well expressed in SHexpCP cells. Total
expression was again even higher in BL21*CP cells, however at
the cost of a lower fraction of soluble protein and an increased con-
tent in truncated products (Fig. S5). While even in SHexpCP cells
GB1 was a less powerful solubility enhancer than DsbA (about
50% remaining in the insoluble fraction of the lysates; Fig. 2C ver-
sus Fig. S5), GB1-Salp15 and GB1-Iric were easily enriched by IMAC
(data not shown). Removal of the bulk of truncated products from
GB1-Salp15 required SEC (shown in Fig. 11A, left panel, for 15N
labeled protein) and some of the protein was lost during subse-
quent concentration by ultraﬁltration. Still, 1H–15N HSQC spectra
revealed the same signiﬁcant peak dispersion for the Salp15 part
as in free wild-type Salp15 (Fig. 11A, right panel; red spectrum: free
Salp15, blue spectrum: GB1-Salp15; a higher magniﬁcation isd structural analysis by NMR. GB1-Salp15 and GB1-Iric-1, including in 15N-labeled
15. Like the unlabeled protein, 15N-GB1-Salp15 contained substantial amounts of
aining the full-length fusion protein were concentrated and used to record 1H–15N
Salp15). (B) Iric-1. 15N-GB1-Iric-1 contained fewer truncated products after IMAC,
embrane (50 k) depleted a larger contaminant (*; retained, ret.). GB1-Iric-1 in the
0 k) and used to record 1H–15N HSQC spectra (lower right panel). Larger versions of
the GB1-Iric-1 fusion protein. TALOS-N was used to predict the secondary structure
indicates the probability to form a-helix (black bars) or b-strand (grey bars). Strip
nce context marked with a helix symbol and an arrow) are shown in Fig. S7. The
up to residue V43 whereas T44 and L45 might be involved in a b-strand according
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from the GB1 part (peak assignment was done using the known
chemical shifts of GB1; [40]). For GB1-Iric-1, the lesser content in
smaller products after IMAC allowed to replace the SEC step by
simple ultraﬁltration; a larger contaminant (marked with * in
Fig. 11B, left panel) was depleted by using a 50 kDa molecular
weight cut-off (MWCO) ﬁlter membrane, and the GB1-Iric-1 pro-
tein in the ﬂow-through could be concentrated, without substan-
tial losses, by subsequent ultraﬁltration using a 10 kDa MWCO
membrane (Fig. 11B, left panel). In this way, 1 ml of GB1-Iric-1 at
about 1.5 mg/ml was obtained from 250 ml of E. coli culture.
1H–15N HSQC spectra revealed a large number of widely dispersed
Iric-1 speciﬁc peaks (Fig. 11B, right panel; a higher magniﬁcation is
shown in Fig. S6B), many of which overlapped with the peaks seen
for DsbA released free Iric-1. Hence substantial parts of Iric-1 in the
GB1 fusion protein appear to adopt the same stable fold as in the
absence of GB1 part.
Using the same protocol, we obtained a ﬁrst sample 0.08 mM
sample of uniformly 13C/15N double-labeled GB1-Iric-1. Despite the
low protein concentration and considerable broadening of a num-
ber of backbone amide resonances standard 3D triple-resonance
spectra allowed up to now the backbone assignment of 54 Iric-1
residues in the fusion protein. Evaluation of the assigned chemical
shifts using TALOS-N [41] and analysis of 15N-edited 3D NOESY
spectra show an unstructured, ﬂexible N-terminus (V21-L45), an
a-helix encompassing residues P54QKLALEL61 and a b-strand
involving residues V104 to D107, as graphically summarized in
Fig. 11C. Pertinent sections of the NOESY spectra for the latter ele-
ments are shown in Fig. S7. In addition, the Cb shifts (39.5 ppm and
42.2 ppm, respectively) of C114 (C4) and C121 (C5) clearly indicate
their involvement in disulﬁde bridges. These data experimentally
support sequence-based secondary structure predictions (see
Section 3) and are in line with the loss of structure in the Cys-free
Iric-1 and Salp15 proteins. Hence for future determination of the
complete 3D structure of the tick Salp15 ortholog family
GB1-Iric-1 appears as a most promising candidate.
3. Discussion
The current lack of efﬁcient expression systems for tick salivary
proteins severely hampers progress in better understanding the
molecular interplay between vector, pathogen and host in general,
and the development of anti-tick vaccines in particular. While
secretory expression in insect cells yields (near) authentic recom-
binant forms of Salp15 and Iric-1, E. coli based systems provide
numerous advantages, including easy handling and access to
mutant proteins, potentially in milligram amounts. However, such
bacterially expressed tick proteins would only be useful if they
mimic important features of their natural, glycosylated counter-
parts. The results of this study show that fusion of wild-type
Salp15 and Iric-1 to the DsbA partner enables generation of pre-
parative amounts of highly soluble, monomeric fusion proteins
retaining the ability to bind to a proven biological interaction part-
ner, i.e. Borrelia OspC; that the DsbA fusion proteins, especially in
combination with site-directed mutants, are useful for epitope
mapping studies; that from slightly modiﬁed DsbA fusions free
Salp15 and Iric-1 can be generated in amounts approaching those
required for structural studies, including in isotope-labeled form;
and that the wild-type forms of the recombinant tick proteins
are folded to a substantial extent in a cysteine-dependent fashion.
While fully establishing the similarities and potential differences
to the genuine tick saliva proteins will require further evaluation,
altogether our results should greatly facilitate future investigations
into the biology of tick saliva proteins and the determination of
their 3D structure.3.1. Impact of the fusion partner and expression strain upon Salp15/
Iric-1 solubility in E. coli
All fusion partners tested, including a simple N terminal His6-
tag, led to high level expression yet only MBP, both forms of DsbA
(Fig. 2, Fig. 10) and, less pronouncedly, GB1 (Fig. S5) mediated sub-
stantial solubility. Regarding the expression strain, total fusion
protein levels were higher in E. coli BL21*CP than in SHexpCP cells,
however, the levels of soluble protein per culture volume of SHe-
xpCP cells were comparable and accompanied by lower levels of
degradation products, thus simplifying puriﬁcation (Fig. 3). This
was corroborated by the efﬁcient soluble expression of numerous
Salp15 and Iric-1 cysteine (Fig. 4) and truncation variants (Fig. 5),
as well as analogous TEV protease cleavable fusion proteins
(Fig. 9). Plausibly, the more reducing intracellular environment in
the SHexpCP versus BL21*CP cells favors formation of (an) intracel-
lular disulﬁde bond(s), as is supported by the presence of the pro-
tease-released proteins in apparently one dominant form
regarding cysteine-status (Fig. 10A); the more stable fold would
reduce sensitivity towards proteolysis. Hence for most down-
stream applications using DsbA Salp15 or Iric fusions in SHexpCP
cells appears as the combination of choice. A potential DsbA alter-
native might be DsbC [42]; in pilot experiments DsbC-Salp15 was
well expressed and soluble yet a ﬁnal statement will require a
quantitative comparison with the DsbA fusions. GB1 did not per-
form quite as well in terms of solubility enhancement (Fig. S5),
however for NMR its small size and the concomitant dispensability
of further processing provide a distinct advantage.
3.2. MAbs raised against E. coli expressed Salp15 are cross-reactive
with Iric-1 and secreted, glycosylated Salp15
As yet no monoclonal antibodies speciﬁc for Salp15 or its ortho-
logs have been described. While the solubilized NHis-Salp15 pro-
tein used as immunogen turned out to be structurally
heterogeneous (Fig. 10B), both mouse mAbs speciﬁcally recognized
the DsbA-Salp15 and DsbA-Iric-1 fusions protein in denaturing
(Western blot; Figs. 4 and 5) and non-denaturing (ELISA; Fig. 7)
formats. Epitope mapping, enabled by numerous DsbA-fused vari-
ants (Figs. 4 and 5), showed that mAbs 19/7.4 and 18/12.1 recog-
nize closely juxtaposed but distinct sequences (I83-N92, and
D88-H99; see summary in Fig. 12). Recognition by mAb 18/12.1,
but not mAb 19/7.4, was strictly dependent on the presence of cys-
teine C3. Because mAb 18/12.1 binding occurred after SDS–PAGE
under reducing conditions, it is likely that C3 per se, rather than
its involvement in a speciﬁc disulﬁde bond, contributes to the epi-
tope. The epitope region is completely conserved in Iric-1 and, with
few chemically similar replacements, in other orthologs (see align-
ment in Fig. S1) as well as in recent isolates from Chinese ticks [43].
Its potential immuno-dominance in the genuine tick saliva pro-
teins remains to be determined; however, in a PepScan assay
[21] overlapping 20-mer peptides representing Salp15 residues
72-91 (there called P6) and 82-101 (P7) were the only ones, in
addition to the most C terminal peptides (P10, P11), that were rec-
ognized by polyclonal anti-Salp15 antisera, suggesting a strong
immunogenicity. Hence mAbs 19/7.4 and 18/12.1 with their dis-
tinct binding sites in this region appear as valuable new tools for
further basic research into the functions of Salp15 proteins. Fur-
thermore, if the mapped mAb epitopes were protective, their con-
servation amongst different orthologs suggests that vaccination
with a saliva protein from one tick species may cross-protect
against other ticks. Most important for potential vaccination
approaches, both mAbs also recognized glycosylated Salp15
(Fig. 6), indicating that their epitopes are not shielded by the gly-
can moieties. Hence pursuing E. coli produced, non-glycosylated
Fig. 12. Schematic summary of functional interfaces and structural features in
Salp15 and Iric-1. The bars represent, to scale, the primary sequences of signal
sequence-less Salp15 and Iric-1. Y-shaped objects symbolize N-glycosylation
motifs, upward and downward pointing marks indicate the positions of the seven
Cys-residues. Secondary structure motifs (a-helix, b-strand) as predicted by Phyre2
are depicted inside the bars, disorder predictions above and below the bars.
Interaction sites deﬁned in this study (applying to both Salp15 and Iric-1), and
secondary structure elements deﬁned by NMR of GB1-Iric-1 are shown in red;
binding to murine CD4 has previously been mapped to the C terminal 20 aa of
Salp15 [44].
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3.3. A charged a-helix containing region within Salp15 and Iric-1
mediates interaction with OspC variants from different borreliae
B. burgdorferi transmission enhancement by Salp15 is thought
to rely at least in part on its recruitment to OspC [21], a rather var-
iable protein on the spirochete surface. OspC binding has also been
shown for insect-cell derived Iric-1 [33]. In vitro afﬁnities to OspC
variants from B. burgdorferi, B. garinii and B. afzelii were all in the
low micromolar range, although protection against antibody-med-
iated killing of the bacteria was observed only for B. burgdorferi
sensu stricto. Our immobilized OspC-binding ELISA using the E.
coli-derived DsbA fused wild-type Salp15 and Iric-1 gave largely
congruent results (Fig. 7; Fig. S2), except that the two B. burgdorferi
OspCs reacted more strongly than their B. afzelii and B. garinii coun-
terparts. The high reactivity of Cys-free Salp15, but not Iric-1, with
the latter two OspCs may relate to better accessibility of the OspC
binding region (see below) due to the lack of global structure (see
below) and the primary sequence differences between Salp15 and
Iric-1 in this region. Clearly, however, OspC binding required nei-
ther cysteines nor a complex 3D structure context because speciﬁc
binding was recapitulated by GFP fusions carrying just residues
48–67 of either Salp15 or Iric-1 (Fig. 8). This agrees well with
recent PepScan data according to which peptide P4 (residues 52-
71 in our numbering system) is involved in OspC binding [21];
however, we found no evidence for the proposed contribution of
C terminal residues, inferred from positive signals with peptide
P11 (aa 116-135) which previously was reported to mediate CD4
binding [44]. Notably, within the sequence 48–67 residues 54–64
of both Salp15 and Iric-1 are predicted, e.g. by Phyre2 [45], to form
an a-helix (the only one in the whole protein; see Fig. 12) which
for residues 54–61 in GB1-Iric-1 is directly conﬁrmed by our
NMR data (see below). Remarkably, the basic residues K60 and
K63 in Salp15 are both replaced by acidic residues in Iric-1 (E60,
E63) yet both proteins interact equally well with OspC. A plausible
explanation comes from the structure of OspC. OspC forms a mush-
room-like symmetrical dimer [46,47], and a cavity in the dimer-
interface in the stalk comprising a central patch of chargedresidues (K60, E61, E63; plus the homologous residues from the
second subunit) lined by hydrophobic aa is proposed to act as
ligand-binding domain [48]. As the KEXE motif is conserved in vir-
tually all known OspC isolates, using slightly different electrostatic
and hydrophobic interactions Salp15 and Iric-1 could still bind to
the same target region on different OspC orthologs. The easy access
to mutants provided by our E. coli expression system lends itself to
further deﬁne the sequence and structure requirements for this
interaction. Given the importance of Salp15/Iric-1 residues 48–67
for OspC binding this region also represents a prime target for neu-
tralizing antibodies. Hence it will be important to evaluate poly-
clonal antisera against Salp15 and Iric-1 for their ability to
recognize this region; if conﬁrmed, the a-helix would also lend
itself for epitope-focused vaccines in which a structured epitope
is stabilized by its presentation on a matching protein scaffold [23].
3.4. Towards the 3D structure of Salp15 family proteins
Understanding the molecular interactions of the tick saliva pro-
teins with the host as well as with tick-vectored pathogens will
eventually require detailed structural knowledge. Our E. coli based
system for soluble expression of free Salp15/Iric-1 by post-expres-
sion proteolytic cleavage and as fusions to the small NMR compat-
ible GB1 tag represent the ﬁrst approach with good prospects for
such direct structural studies. The biological relevance of these
proteins as models for the genuine tick saliva proteins is sup-
ported, though not proven, by their ability to induce mAbs that rec-
ognize glycosylated Salp15, and to speciﬁcally interact with
various OspC proteins. Practically, our data demonstrate the suit-
ability of the expression and puriﬁcation protocols to obtain 15N
and 13C/15N labeled samples for NMR analyses. The 2D spectra of
the protease-released tick proteins (Fig. 10D, E; Fig. S4A, B), limited
in sensitivity by the low solubility of free wild-type Iric-1 and par-
ticularly Salp15, still revealed a negative impact on general struc-
tural stability by replacement of the endogenous cysteines. This
is not unexpected given that Cys-containing secretory proteins
commonly contain disulﬁde bonds. Hence the better soluble Cys-
free variants seem not suitable for structural work. However, the
enhanced solubility of the GB1 fusions with the wild-type proteins
and the preliminary NMR data obtained with the 13C/15N double-
labeled GB1-Iric-1 appear most promising.
Primary sequence-based structure predictions have become
powerful tools, especially if they involve template-based homology
modeling such as Phyre2 [45] or Porter+[49]. Both predict for
Salp15 and Iric-1 an a-helix from residues 54–66, and some
regions with b-strand propensity (Fig. 12); Phyre2 also implies dis-
order for the N terminal region up to position 40, and the C termi-
nal region downstream of position 117. However, the lack of
homologs of known structure substantially limits reliability of
the predictions. Notably, our preliminary NMR data for GB1-Iric-
1 indicate indeed an a-helix for residues P54-L61 (Fig. S7), lending
credit to the predictions. Interestingly, the charged residues K56
and E60 (plus E63 if the helix was slightly longer) are on one face,
neighbored by hydrophobic residues, and the same arrangement of
charged versus hydrophobic residues would hold for Salp15. Its
relevance for the interaction with OspC (and possibly other, host-
encoded proteins) might now easily be tested by mutations. The
NMR data also reveal a b-strand involving at least V104-D107
(Fig. S7), plus the participation in disulﬁde bridges of C114 and
C121, possibly between these two residues; neither of the above
prediction programs provides information on disulﬁde bridges.
While as yet giving only a glimpse into the structural features of
Iric-1, solving the complete 3D structure of Salp15 family tick pro-
teins appears now in reach. This will enable the rational design of
vaccines that overcome their immunosuppressive properties and
induce neutralizing antibodies. Our study also implies E. coli as a
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required amounts.4. Materials and methods
4.1. Prokaryotic expression vectors
pET28-derived vectors encoding N terminally His6-tagged
DsbA, GB1, GST, MBP, or Trx fused to eGFP were kindly provided
by Jerome Basquin (EMBL, Heidelberg, Germany). Synthetic, E. coli
codon usage-optimized genes for Salp15 (Genbank: AAK97817.1)
and Iric-1 (Genbank: ABU93613.1) comprising terminal Nco I and
Hind III sites (obtained from Entelechon and GeneArt, respectively)
were then used to replace the eGFP ORF ﬂanked by the same
restriction sites. Most variants were constructed using conven-
tional mutagenic PCR. Vector pET28-NHis-GFP was obtained from
the pET28-GB1-eGFP vector via deletion of the GB1-internal Hind
III–Nco I fragment so as to leave only the His6-tag plus ﬁve
GB1N terminal residues upstream of eGFP. GFP vectors encoding
C terminal fusions with the Salp15 segment P48-D67 and the
Iric-1 segment P48-N67 were obtained by cloning appropriate syn-
thetic oligonucleotide duplexes between the 30 proximal BsrG I site
in the eGFP ORF and the Kpn I site immediately following the eGFP
stop codon. The construct for NH6-Salp15 was obtained by insert-
ing a leader-less PCR-ampliﬁed Salp15 cDNA into the BamH I site of
pQE-30 Xa (Qiagen), such that the mature Salp15 sequence starting
with V19 was preceded by the aa sequence
MRGSHHHHHHGSGSGSGIEGRPYNGTGS; the factor Xa recognition
sequence is underlined. For expression of the B. afzelii NE [34] OspC
variants A3 (Genbank: AFA85556.1) and YU (Genbank:
AIK19145.1), leader-less versions of the corresponding cDNAs were
similarly cloned into pQE-30 Xa. pGEX-2T vectors (GE Healthcare)
encoding GST-tagged leader-less B. burgdorferi ZS7 OspCa (Gen-
bank: AAM19715.1) and OspCb (containing the following
exchanges compared to OspCa: D87G, N88D, R92H, A133E,
T135S, D136T, N140D, E141N, S144Q, K147I, K148Q, D149G,
A150V, D153E, D154E) were previously described [50]. All con-
structs were veriﬁed by DNA sequencing.
4.2. Recombinant tick protein and OspC expression in E. coli
The respective Salp15 and Iric-1 expression vectors were trans-
formed into E. coli BL21*CP (Stratagene) or T7 SHufﬂe express
(NEB) cells carrying the CP rare tRNA plasmid. Expression was
induced by addition of IPTG to a ﬁnal concentration of 1 mM,
and the cultures (usually 250 ml Luria broth containing appropri-
ate antibiotics) were shaken in bafﬂed ﬂasks for 16 h at 22 C.
Cleared lysates were obtained via treatment, in the presence of
protease inhibitor cocktail without EDTA (Roche), with Triton
X-100 and lysozyme plus benzonase, sonication and removal of
insoluble material by centrifugation as previously described [51];
in addition, the supernatants were passed through 0.22 lm sterile
ﬁlters before further work-up. OspCa and OspCb were expressed as
GST fusions in E. coli JM109 cells via induction with 1 mM IPTG for
3 h at 37 C and afﬁnity puriﬁcation on glutathione sepharose 4B
(GE Healthcare), followed by release from GST via factor Xa
cleavage as described [52]. OspC A3 and OspC YU were expressed
in E. coli B834(DE3) cells (Novagen) without IPTG addition, and
puriﬁed by manual Ni2+ IMAC on Ni-NTA agarose beads (Qiagen).
4.3. Puriﬁcation of Salp15 and Iric-1 fusion proteins from E. coli
For Ni2+-IMAC cleared bacterial lysates from 250 ml cultures
were passed through a 1 ml Ni-NTA Superﬂow cartridge (Qiagen)
mounted on an ÄKTA FPLC system (GE Healthcare, Unicornsoftware) and equilibrated in TN 150 buffer (25 mM Tris/HCl,
150 mM NaCl, pH 7.5) supplemented with 20 mM imidazole, fol-
lowed by application of a linear gradient from 20 mM to 640 mM
imidazole. His6-tagged proteins usually eluted between 100 mM
to 300 mM imidazole and were collected in 1 ml fractions. Where
appropriate, the peak fractions (usually around 4 ml) were sub-
jected to SEC on a Superdex 75 16/60 column (GE Healthcare)
equilibrated in TN150 buffer. After elution of 0.3 column volumes,
2 ml fractions were collected and analyzed by SDS–PAGE. Apparent
molecular masses were determined from the elution volumes of a
set of marker proteins of known sizes (BioRad gel ﬁltration stan-
dard). If desired, proteins were concentrated via ultraﬁltration
through Amicon Ultra centrifugal ﬁlters (EMD Millipore) with
appropriate molecular weight cut offs.
4.4. TEV protease-mediated release of Salp15 and Iric-1 from DsbA-
TEV fusion proteins
The S129V variant of His6-tagged TEV protease was expressed
from plasmid pRK793 plasmid essentially as described [53]. After
Ni2+-IMAC, the protein was dialysed against TN50 containing
5 mM DTT plus 2 mM EDTA and concentrated using a 10 MWCO
Amicon centrifugal ﬁlter to 1.5 mg/ml. Stock solutions containing
10% glycerol were stored at 20 C. Digestions were usually per-
formed at 4 C over night or 4 h at 16 C using a ﬁnal concentration
of 25 lg/ml TEV protease and a 50-fold to 100-fold mass excess of
DsbA-TEV fusion protein substrate. Released Salp15 was obtained
by removal of His-tagged uncleaved fusion protein, released DsbA
and TEV protease by collecting the ﬂow-through from a Ni-NTA
superﬂow column as described above. For released Iric-1, the
undesired His-tagged components were removed using Ni-NTA
agarose in a batch procedure.
4.5. Solubilization of NH6-Salp15 from inclusion bodies
Cells from a 2 L culture of induced E. coli JM109 cells trans-
formed with the pQE-30 Xa-NHis-Salp vector were incubated on
ice in 50 mL BugBuster reagent (Novagen) for 30 min, followed
by centrifugation at 20,000g. The insoluble pellet containing the
bulk of Salp15 was washed twice in 50 mL MT-PBS buffer
(150 mM NaCl, 16 mM Na2HPO4, 4 mM NaH2PO4; pH 7.4) and dis-
solved in 10 ml TPI-5 buffer (10 mM Tris/HCl, 100 mM NaH2PO4,
5 mM imidazole, pH 8.0) containing 8 M urea. Insoluble material
was removed by centrifugation (20,000g, 10 min, 23 C) and the
supernatant was passed through a 5 ml (gel bed) Ni2+-NTA Sephar-
ose (Qiagen) column. The column was washed with 2 gel bed vol-
umes of 8 M urea in TPI-20 buffer (like TPI-5 but containing 20 mM
imidazole) and bound proteins were eluted with 2 gel bed volumes
of 8 M urea in TPI-500 buffer (as TPI-5 but containing 500 mM
imidazole). The eluate was transferred into a dialysis tubing (6–
8 kDa MWCO; Spectrapor) and initially dialysed against 200 ml
of 8 M urea in MT-PBS buffer. The urea concentration was gradu-
ally reduced to 0.3 M by dropwise addition (4 ml/min) of a total
of 5 L MT-PBS; thereafter dialysis was continued against MT-PBS
without urea for 4 h. Insoluble material was removed by centrifu-
gation at 10,000g for 10 min. Soluble protein in the supernatant
was concentrated by ultraﬁltration.
4.6. 15N and 13C/15N labeling
For labeling with NMR-active isotopes, DsbA-TEV Salp15 and
Iric-1 proteins were expressed as described above except that 2 h
prior to induction with IPTG, precultures grown in LB medium
were transferred into minimal M9 medium [54] containing 15NH4-
Cl (Sigma), or 15NH4Cl plus 13C glucose (Deutero) as the only nitro-
gen and carbon sources, respectively.
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The hGFP coding sequence in the CMV-IE promoter driven vec-
tor pTR-UF5 [55] was replaced by coding sequences for C termi-
nally His6-tagged Salp15 precursor, ie. containing the authentic
Salp15 signal sequence (pTRUF-SalpSig-Salp15H6), the same con-
taining in addition a GH6 sequence between Salp15 aa 21 and aa
22 (pTRUF-SalpSigNH6-Salp15H6), or the mature Salp15 sequence
aa 20-135 preceded by the E. coli OmpA signal peptide MKKTAIAIA-
VALAGFATVA plus an extra Met residue (pTRUF-OmpA-Salp15H6).
The vectors were transfected into HEK293 cells grown in 10 cm
diameter dishes in DMEM (PAA Laboratories) supplemented with
10% fetal calf serum, 100 U/ml penicillin, and 100 lg/ml strepto-
mycin at 37 C and 5% CO2 using Mirus Transit LT1 reagent as rec-
ommended by the manufacturer. Cell culture supernatants were
harvested on day 4 post transfection. For ELISA-based assays,
200 ll supernatant per well from the transfected cells and, for con-
trol, from cells transfected with a GFP vector or non-transfected
cells, were incubated on Ni-NTA HisSorb (Qiagen) plates as
described below.
For immunoblotting, 5 ml of the respective supernatants were
adsorbed to 100 ll (gel-bed) Ni-NTA agarose beads (Qiagen), and
washed 3with 1 ml of TN150 buffer. Then 20 ll each of the beads
were either directly boiled with 30 ll of SDS sample, or treated
with PNGase F (NEB) as recommended by the manufacturer. After
washing, the beads were likewise analyzed by SDS–PAGE and
immuno-blotting.
4.8. Generation of anti-Salp15 mAbs
MAbs 18/12.1 and 19/7.4 were generated by immunization of
Balb/c mice with solubilized NHis-Salp15 protein in monophos-
phoryl-lipid A (MPL) adjuvant. Spleen cell fusion with myeloma
cells and hybridoma selection were performed as previously
described [35]. Salp15 speciﬁc hybridomas were identiﬁed via
immunoblotting for recognition of the immunization antigen. All
animal research was approved in advance by the Laboratory
Animal Committee of the University of Heidelberg (RP Karlsruhe
35-9185.82/A-43/10) and performed in accordance with the
European Communities Council Directive of 24 November, 1986
(86/609/EEC).
4.9. Immuno-blotting and ELISA
For immunoblotting, proteins were separated by SDS–PAGE,
electro-blotted to polyvinylidenﬂuoride (PVDF) membranes (Milli-
pore) and probed as previously described [51]. For detection of His-
tagged proteins, a Tetra-His mouse mAb (Qiagen) was used; Salp15
proteins were detected using mAbs 19/7.4 or 18/12.1. Bound mAbs
were visualized using peroxidase- (PO-) conjugated anti-mouse
antibody (Dianova) and ECL reagent (GE Healthcare), followed by
exposure to X-ray ﬁlm (BioMax MR, Kodak).
For ELISA, the desired proteins were immobilized on 96 well
NUNC Maxisorp microtiter plates in coating buffer (50 mM Na2-
CO3, pH 9.6). Plates were washed three times in PBST buffer (phos-
phate buffer saline containing 0.05 % Tween-20) and blocked for
1 h at RT in blocking buffer (PBS containing 1% BSA). All additional
incubations were performed in binding buffer (PBS containing 0.1%
BSA) for 1 h at RT. For detection of secreted His-tagged Salp15
derivatives, pre-blocked Ni-NTA HisSorb plates (Qiagen) plates
were employed as recommended by the manufacturer. Bound anti-
bodies were detected using appropriate secondary antibody-PO
conjugates (Dianova) with tetramethylbenzidine (TMB; Sigma) as
substrate. Absorbance at 450 nm (A450nm) was monitored using a
Genios Pro plate reader (Tecan). All assays were performed inquadruplicate. Mean values and standard error of the mean
(SEM) were calculated using Graphpad Prism.
4.10. NMR spectroscopy
All NMR spectra were collected at 298 or 304 K on a Bruker
Avance 600 MHz instrument equipped with a 5 mm TXI cryoprobe.
1H, 15N, and 13C chemical shift assignments of GB1-Iric-1 in
100 mM sodium phosphate (pH 6) and 10% D2O (v/v) were
obtained using standard strategies based on 1H–15N HSQC spectra
and the following 3D experiments: HNCA, HN(CO)CA, CBCA(-
CO)NH, CBCANH, HNCO, HN(CA)CO, HBHA(CO)NH and NOE-
SY-1H–15N-HSQC (100 ms mixing time). All chemical shifts were
referenced to internal 2,2-dimethyl-2-silapentane-5-sulfonic acid
(DSS). NMR data were processed with Bruker’s Topspin 2.1 soft-
ware and analyzed with CARA [56]. The TALOS-N [41] web server
(http://spin.niddk.nih.gov/bax/nmrserver/talosn/) was used for
chemical shift based identiﬁcation of secondary structure
elements.
Author contributions
P.K., D.B., R.W. and M.N. designed research; P.K., D.B., J.V., J.H.,
and M.N. performed research; P.K., D.B., R.W. and M.N. analyzed
data; and P.K., D.B., R.W. and M.N. wrote the paper.
Acknowledgements
This work was supported by the Deutsche Forschungsgemeins-
chaft through grants NA 154/11-1 to M.N. and WA 533/8-1 to R.W.
D.B. acknowledges continued support by Dr. B. Fakler (Univer-
sity of Freiburg).
Appendix A. Supplementary data
Supplementary data associated with this article can be found, in
the online version, at http://dx.doi.org/10.1016/j.fob.2014.12.002.
References
[1] Brossard, M. and Wikel, S.K. (2004) Tick immunobiology. Parasitology 129
(Suppl.), S161–S176.
[2] Charrel, R.N., Attoui, H., Butenko, A.M., Clegg, J.C., Deubel, V., Frolova, T.V.,
Gould, E.A., Gritsun, T.S., Heinz, F.X., Labuda, M., Lashkevich, V.A., Loktev, V.,
Lundkvist, A., Lvov, D.V., Mandl, C.W., Niedrig, M., Papa, A., Petrov, V.S.,
Plyusnin, A., Randolph, S., Suss, J., Zlobin, V.I. and de Lamballerie, X. (2004)
Tick-borne virus diseases of human interest in Europe. Clin. Microbiol. Infect.
10, 1040–1055.
[3] Labuda, M. and Nuttall, P.A. (2004) Tick-borne viruses. Parasitology 129
(Suppl.), S221–S245.
[4] Perronne, C. (2014) Lyme and associated tick-borne diseases: global
challenges in the context of a public health threat. Front. Cell. Infect.
Microbiol. 4, 74.
[5] Stanek, G., Wormser, G.P., Gray, J. and Strle, F. (2012) Lyme borreliosis. Lancet
379, 461–473.
[6] Radolf, J.D., Caimano, M.J., Stevenson, B. and Hu, L.T. (2012) Of ticks, mice and
men: understanding the dual-host lifestyle of Lyme disease spirochaetes. Nat.
Rev. Microbiol. 10, 87–99.
[7] Stibraniova, I., Lahova, M. and Bartikova, P. (2013) Immunomodulators in tick
saliva and their beneﬁts. Acta Virol. 57, 200–216.
[8] Anguita, J., Ramamoorthi, N., Hovius, J.W., Das, S., Thomas, V., Persinski, R.,
Conze, D., Askenase, P.W., Rincon, M., Kantor, F.S. and Fikrig, E. (2002) Salp15,
an ixodes scapularis salivary protein, inhibits CD4(+) T cell activation.
Immunity 16, 849–859.
[9] Juncadella, I.J. and Anguita, J. (2009) The immunosuppresive tick salivary
protein, Salp15. Adv. Exp. Med. Biol. 666, 121–131.
[10] Juncadella, I.J., Garg, R., Ananthnarayanan, S.K., Yengo, C.M. and Anguita, J.
(2007) T-cell signaling pathways inhibited by the tick saliva
immunosuppressor, Salp15. FEMS Immunol. Med. Microbiol. 49, 433–438.
[11] Mason, L.M., Veerman, C.C., Geijtenbeek, T.B. and Hovius, J.W. (2014) Menage
a trois: Borrelia, dendritic cells, and tick saliva interactions. Trends Parasitol.
30, 95–103.
P. Kolb et al. / FEBS Open Bio 5 (2015) 42–55 55[12] Hovius, J.W., Ramamoorthi, N., Van’t Veer, C., de Groot, K.A., Nijhof, A.M.,
Jongejan, F., van Dam, A.P. and Fikrig, E. (2007) Identiﬁcation of Salp15
homologues in Ixodes ricinus ticks. Vector Borne Zoonotic Dis. 7, 296–303.
[13] Nuttall, P.A. and Labuda, M. (2004) Tick-host interactions: saliva-activated
transmission. Parasitology 129 (Suppl.), S177–S189.
[14] Wikel, S. (2013) Ticks and tick-borne pathogens at the cutaneous interface.
host defenses, tick countermeasures, and a suitable environment for pathogen
establishment. Front. Microbiol. 4, 337.
[15] Liu, X.Y. and Bonnet, S.I. (2014) Hard tick factors implicated in pathogen
transmission. PLoS Negl. Trop. Dis. 8, e2566.
[16] Ramamoorthi, N., Narasimhan, S., Pal, U., Bao, F., Yang, X.F., Fish, D., Anguita, J.,
Norgard, M.V., Kantor, F.S., Anderson, J.F., Koski, R.A. and Fikrig, E. (2005) The
Lyme disease agent exploits a tick protein to infect the mammalian host.
Nature 436, 573–577.
[17] Schuijt, T.J., Hovius, J.W., van Burgel, N.D., Ramamoorthi, N., Fikrig, E. and van
Dam, A.P. (2008) The tick salivary protein Salp15 inhibits the killing of serum-
sensitive Borrelia burgdorferi sensu lato isolates. Infect. Immun. 76, 2888–
2894.
[18] Schuijt, T.J., Hovius, J.W., van der Poll, T., van Dam, A.P. and Fikrig, E. (2011)
Lyme borreliosis vaccination: the facts, the challenge, the future. Trends
Parasitol. 27, 40–47.
[19] Embers, M.E. and Narasimhan, S. (2013) Vaccination against Lyme disease:
past, present, and future. Front. Cell. Infect. Microbiol. 3, 6.
[20] Stricker, R.B. and Johnson, L. (2014) Lyme disease: call for a ‘‘Manhattan
Project’’ to combat the epidemic. PLoS Pathog. 10, e1003796.
[21] Dai, J., Wang, P., Adusumilli, S., Booth, C.J., Narasimhan, S., Anguita, J. and
Fikrig, E. (2009) Antibodies against a tick protein, Salp15, protect mice from
the Lyme disease agent. Cell Host Microbe 6, 482–492.
[22] Walker, A., Skamel, C. and Nassal, M. (2011) SplitCore: an exceptionally
versatile viral nanoparticle for native whole protein display regardless of 3D
structure. Sci. Rep. 1, 5.
[23] Correia, B.E., Bates, J.T., Loomis, R.J., Baneyx, G., Carrico, C., Jardine, J.G., Rupert,
P., Correnti, C., Kalyuzhniy, O., Vittal, V., Connell, M.J., Stevens, E., Schroeter, A.,
Chen, M., Macpherson, S., Serra, A.M., Adachi, Y., Holmes, M.A., Li, Y., Klevit,
R.E., Graham, B.S., Wyatt, R.T., Baker, D., Strong, R.K., Crowe Jr., J.E., Johnson,
P.R. and Schief, W.R. (2014) Proof of principle for epitope-focused vaccine
design. Nature 507, 201–206.
[24] de Marco, A. (2009) Strategies for successful recombinant expression of
disulﬁde bond-dependent proteins in Escherichia coli. Microb. Cell Factors 8,
26.
[25] Lebendiker, M. and Danieli, T. (2014) Production of prone-to-aggregate
proteins. FEBS Lett. 588, 236–246.
[26] Lobstein, J., Emrich, C.A., Jeans, C., Faulkner, M., Riggs, P. and Berkmen, M.
(2012) SHufﬂe, a novel Escherichia coli protein expression strain capable of
correctly folding disulﬁde bonded proteins in its cytoplasm. Microb. Cell
Factors 11, 56.
[27] Waugh, D.S. (2005) Making the most of afﬁnity tags. Trends Biotechnol. 23,
316–320.
[28] Young, C.L., Britton, Z.T. and Robinson, A.S. (2012) Recombinant protein
expression and puriﬁcation: a comprehensive review of afﬁnity tags and
microbial applications. Biotechnol. J. 7, 620–634.
[29] Ito, K. and Inaba, K. (2008) The disulﬁde bond formation (Dsb) system. Curr.
Opin. Struct. Biol. 18, 450–458.
[30] Zapun, A., Cooper, L. and Creighton, T.E. (1994) Replacement of the active-site
cysteine residues of DsbA, a protein required for disulﬁde bond formation
in vivo. Biochemistry 33, 1907–1914.
[31] Zhang, Y., Olsen, D.R., Nguyen, K.B., Olson, P.S., Rhodes, E.T. and Mascarenhas,
D. (1998) Expression of eukaryotic proteins in soluble form in Escherichia coli.
Protein Expr. Purif. 12, 159–165.
[32] Zhou, P., Lugovskoy, A.A. and Wagner, G. (2001) A solubility-enhancement tag
(SET) for NMR studies of poorly behaving proteins. J. Biomol. NMR 20, 11–14.
[33] Hovius, J.W., Schuijt, T.J., de Groot, K.A., Roelofs, J.J., Oei, G.A., Marquart, J.A., de
Beer, R., van‘t Veer, C., van der Poll, T., Ramamoorthi, N., Fikrig, E. and van Dam,
A.P. (2008) Preferential protection of Borrelia burgdorferi sensu stricto by a
Salp15 homologue in Ixodes ricinus saliva. J. Infect. Dis. 198, 1189–1197.
[34] Perez, D., Kneubuhler, Y., Rais, O., Jouda, F. and Gern, L. (2011) Borrelia afzelii
ospC genotype diversity in Ixodes ricinus questing ticks and ticks from rodents
in two Lyme borreliosis endemic areas: contribution of co-feeding ticks. Ticks
Tick Borne Dis. 2, 137–142.
[35] Kramer, M.D., Schaible, U.E., Wallich, R., Moter, S.E., Petzoldt, D. and Simon,
M.M. (1990) Characterization of Borrelia burgdorferi associated antigens by
monoclonal antibodies. Immunobiology 181, 357–366.[36] Shin, J. and Lee, W. (2008) Structural proteomics by NMR spectroscopy. Expert
Rev. Proteomics 5, 589–601.
[37] Kwan, A.H., Mobli, M., Gooley, P.R., King, G.F. and Mackay, J.P. (2011)
Macromolecular NMR spectroscopy for the non-spectroscopist. FEBS J. 278,
687–703.
[38] Rath, A., Glibowicka, M., Nadeau, V.G., Chen, G. and Deber, C.M. (2009)
Detergent binding explains anomalous SDS–PAGE migration of membrane
proteins. Proc. Natl. Acad. Sci. USA 106, 1760–1765.
[39] Zhou, P. and Wagner, G. (2010) Overcoming the solubility limit with
solubility-enhancement tags: successful applications in biomolecular NMR
studies. J. Biomol. NMR 46, 23–31.
[40] Gronenborn, A.M., Filpula, D.R., Essig, N.Z., Achari, A., Whitlow, M., Wingﬁeld,
P.T. and Clore, G.M. (1991) A novel, highly stable fold of the immunoglobulin
binding domain of streptococcal protein G. Science 253, 657–661.
[41] Shen, Y. and Bax, A. (2013) Protein backbone and sidechain torsion angles
predicted from NMR chemical shifts using artiﬁcial neural networks. J. Biomol.
NMR 56, 227–241.
[42] Nozach, H., Fruchart-Gaillard, C., Fenaille, F., Beau, F., Ramos, O.H., Douzi, B.,
Saez, N.J., Moutiez, M., Servent, D., Gondry, M., Thai, R., Cuniasse, P.,
Vincentelli, R. and Dive, V. (2013) High throughput screening identiﬁes
disulﬁde isomerase DsbC as a very efﬁcient partner for recombinant
expression of small disulﬁde-rich proteins in E. coli. Microb. Cell Factors 12,
37.
[43] Wang, X., Huang, Y., Niu, S.B., Jiang, B.G., Jia, N., van der Geest, L., Ni, X.B., Sun,
Y. and Cao, W.C. (2014) Genetic diversity of Salp15 in the Ixodes ricinus
complex (Acari: Ixodidae). PLoS ONE 9, e94131.
[44] Garg, R., Juncadella, I.J., Ramamoorthi, N., Ashish, Ananthanarayanan.S.K.,
Thomas, V., Rincon, M., Krueger, J.K., Fikrig, E., Yengo, C.M. and Anguita, J.
(2006) Cutting edge: CD4 is the receptor for the tick saliva immunosuppressor,
Salp15. J. Immunol. 177, 6579–6583.
[45] Kelley, L.A. and Sternberg, M.J. (2009) Protein structure prediction on the
Web: a case study using the Phyre server. Nat. Protoc. 4, 363–371.
[46] Kumaran, D., Eswaramoorthy, S., Luft, B.J., Koide, S., Dunn, J.J., Lawson, C.L. and
Swaminathan, S. (2001) Crystal structure of outer surface protein C (OspC)
from the Lyme disease spirochete, Borrelia burgdorferi. EMBO J. 20, 971–978.
[47] Eicken, C., Sharma, V., Klabunde, T., Owens, R.T., Pikas, D.S., Höök, M. and
Sacchettini, J.C. (2001) Crystal structure of Lyme disease antigen outer surface
protein C from Borrelia burgdorferi. J. Biol. Chem. 276, 10010–10015.
[48] Earnhart, C.G., Leblanc, D.V., Alix, K.E., Desrosiers, D.C., Radolf, J.D. and
Marconi, R.T. (2010) Identiﬁcation of residues within ligand-binding domain 1
(LBD1) of the Borrelia burgdorferi OspC protein required for function in the
mammalian environment. Mol. Microbiol. 76, 393–408.
[49] Mooney, C., Vullo, A. and Pollastri, G. (2006) Protein structural motif
prediction in multidimensional phi-psi space leads to improved secondary
structure prediction. J. Comput. Biol. 13, 1489–1502.
[50] Skamel, C., Ploss, M., Böttcher, B., Stehle, T., Wallich, R., Simon, M.M. and
Nassal, M. (2006) Hepatitis B virus capsid-like particles can display the
complete, dimeric outer surface protein C and stimulate production of
protective antibody responses against Borrelia burgdorferi infection. J. Biol.
Chem. 281, 17474–17481.
[51] Vogel, M., Vorreiter, J. and Nassal, M. (2005) Quaternary structure is critical for
protein display on capsid-like particles (CLPs): efﬁcient generation of hepatitis
B virus CLPs presenting monomeric but not dimeric and tetrameric ﬂuorescent
proteins. Proteins 58, 478–488.
[52] Rossmann, E., Kitiratschky, V., Hofmann, H., Kraiczy, P., Simon, M.M. and
Wallich, R. (2006) Borrelia burgdorferi complement regulator-acquiring surface
protein 1 of the Lyme disease spirochetes is expressed in humans and induces
antibody responses restricted to nondenatured structural determinants.
Infect. Immun. 74, 7024–7028.
[53] Kapust, R.B., Tozser, J., Fox, J.D., Anderson, D.E., Cherry, S., Copeland, T.D. and
Waugh, D.S. (2001) Tobacco etch virus protease: mechanism of autolysis and
rational design of stable mutants with wild-type catalytic proﬁciency. Protein
Eng. 14, 993–1000.
[54] Sambrook, J., Fritsch, E.F. and Maniatis, T. (1989) Molecular Cloning - A
Laboratory Manual, second ed, Cold Spring Harbor Laboratory Press, Cold
Spring Harbor, NY.
[55] Zolotukhin, S., Potter, M., Hauswirth, W.W., Guy, J. and Muzyczka, N. (1996) A
‘‘humanized’’ green ﬂuorescent protein cDNA adapted for high-level
expression in mammalian cells. J. Virol. 70, 4646–4654.
[56] Keller, R. (2004) The Computer Aided Resonance Assignment Tutorial,
CANTINA Verlag, Goldau.
